Cargando…

Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis

BACKGROUND: Sepsis is a serious medical condition requiring timely administered, appropriate antibiotic therapy. Blood culture is regarded as the gold standard for aetiological diagnosis of sepsis, but it suffers from low sensitivity and long turnaround time. Thus, nucleic acid amplification tests (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ljungström, Lars, Enroth, Helena, Claesson, Berndt EB, Ovemyr, Ida, Karlsson, Jesper, Fröberg, Berit, Brodin, Anna-Karin, Pernestig, Anna-Karin, Jacobsson, Gunnar, Andersson, Rune, Karlsson, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419503/
https://www.ncbi.nlm.nih.gov/pubmed/25928122
http://dx.doi.org/10.1186/s12879-015-0938-4
_version_ 1782369588420280320
author Ljungström, Lars
Enroth, Helena
Claesson, Berndt EB
Ovemyr, Ida
Karlsson, Jesper
Fröberg, Berit
Brodin, Anna-Karin
Pernestig, Anna-Karin
Jacobsson, Gunnar
Andersson, Rune
Karlsson, Diana
author_facet Ljungström, Lars
Enroth, Helena
Claesson, Berndt EB
Ovemyr, Ida
Karlsson, Jesper
Fröberg, Berit
Brodin, Anna-Karin
Pernestig, Anna-Karin
Jacobsson, Gunnar
Andersson, Rune
Karlsson, Diana
author_sort Ljungström, Lars
collection PubMed
description BACKGROUND: Sepsis is a serious medical condition requiring timely administered, appropriate antibiotic therapy. Blood culture is regarded as the gold standard for aetiological diagnosis of sepsis, but it suffers from low sensitivity and long turnaround time. Thus, nucleic acid amplification tests (NAATs) have emerged to shorten the time to identification of causative microbes. The aim of the present study was to evaluate the clinical utility in everyday practice in the emergency department of two commercial NAATs in patients suspected with sepsis. METHODS: During a six-week period, blood samples were collected consecutively from all adult patients admitted to the general emergency department for suspicion of a community-onset sepsis and treated with intravenous antibiotics. Along with conventional blood cultures, multiplex PCR (Magicplex™) was performed on whole blood specimens whereas portions from blood culture bottles were used for analysis by microarray-based assay (Prove-it™). The aetiological significance of identified organisms was determined by two infectious disease physicians based on clinical presentation and expected pathogenicity. RESULTS: Among 382 episodes of suspected sepsis, clinically relevant microbes were detected by blood culture in 42 episodes (11%), by multiplex PCR in 37 episodes (9.7%), and by microarray in 32 episodes (8.4%). Although moderate agreement with blood culture (kappa 0.50), the multiplex PCR added diagnostic value by timely detection of 15 clinically relevant findings in blood culture-negative specimens. Results of the microarray corresponded very well to those of blood culture (kappa 0.90), but were available just marginally prior to blood culture results. CONCLUSIONS: The use of NAATs on whole blood specimens in adjunct to current culture-based methods provides a clinical add-on value by allowing for detection of organisms missed by blood culture. However, the aetiological significance of findings detected by NAATs should be interpreted with caution as the high analytical sensitivity may add findings that do not necessarily corroborate with the clinical diagnosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0938-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4419503
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44195032015-05-06 Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis Ljungström, Lars Enroth, Helena Claesson, Berndt EB Ovemyr, Ida Karlsson, Jesper Fröberg, Berit Brodin, Anna-Karin Pernestig, Anna-Karin Jacobsson, Gunnar Andersson, Rune Karlsson, Diana BMC Infect Dis Research Article BACKGROUND: Sepsis is a serious medical condition requiring timely administered, appropriate antibiotic therapy. Blood culture is regarded as the gold standard for aetiological diagnosis of sepsis, but it suffers from low sensitivity and long turnaround time. Thus, nucleic acid amplification tests (NAATs) have emerged to shorten the time to identification of causative microbes. The aim of the present study was to evaluate the clinical utility in everyday practice in the emergency department of two commercial NAATs in patients suspected with sepsis. METHODS: During a six-week period, blood samples were collected consecutively from all adult patients admitted to the general emergency department for suspicion of a community-onset sepsis and treated with intravenous antibiotics. Along with conventional blood cultures, multiplex PCR (Magicplex™) was performed on whole blood specimens whereas portions from blood culture bottles were used for analysis by microarray-based assay (Prove-it™). The aetiological significance of identified organisms was determined by two infectious disease physicians based on clinical presentation and expected pathogenicity. RESULTS: Among 382 episodes of suspected sepsis, clinically relevant microbes were detected by blood culture in 42 episodes (11%), by multiplex PCR in 37 episodes (9.7%), and by microarray in 32 episodes (8.4%). Although moderate agreement with blood culture (kappa 0.50), the multiplex PCR added diagnostic value by timely detection of 15 clinically relevant findings in blood culture-negative specimens. Results of the microarray corresponded very well to those of blood culture (kappa 0.90), but were available just marginally prior to blood culture results. CONCLUSIONS: The use of NAATs on whole blood specimens in adjunct to current culture-based methods provides a clinical add-on value by allowing for detection of organisms missed by blood culture. However, the aetiological significance of findings detected by NAATs should be interpreted with caution as the high analytical sensitivity may add findings that do not necessarily corroborate with the clinical diagnosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-0938-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-28 /pmc/articles/PMC4419503/ /pubmed/25928122 http://dx.doi.org/10.1186/s12879-015-0938-4 Text en © Ljungström et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ljungström, Lars
Enroth, Helena
Claesson, Berndt EB
Ovemyr, Ida
Karlsson, Jesper
Fröberg, Berit
Brodin, Anna-Karin
Pernestig, Anna-Karin
Jacobsson, Gunnar
Andersson, Rune
Karlsson, Diana
Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis
title Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis
title_full Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis
title_fullStr Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis
title_full_unstemmed Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis
title_short Clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis
title_sort clinical evaluation of commercial nucleic acid amplification tests in patients with suspected sepsis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419503/
https://www.ncbi.nlm.nih.gov/pubmed/25928122
http://dx.doi.org/10.1186/s12879-015-0938-4
work_keys_str_mv AT ljungstromlars clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT enrothhelena clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT claessonberndteb clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT ovemyrida clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT karlssonjesper clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT frobergberit clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT brodinannakarin clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT pernestigannakarin clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT jacobssongunnar clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT anderssonrune clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis
AT karlssondiana clinicalevaluationofcommercialnucleicacidamplificationtestsinpatientswithsuspectedsepsis